166 related articles for article (PubMed ID: 7875148)
1. Granulocyte-macrophage colony-stimulating factor in combination with pentavalent antimony for the treatment of visceral Leishmaniasis.
Badaró R; Nascimento C; Carvalho JS; Badaró F; Russo D; Ho JL; Reed SG; Johnson WD; Jones TC
Eur J Clin Microbiol Infect Dis; 1994; 13 Suppl 2():S23-8. PubMed ID: 7875148
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human granulocyte-macrophage colony-stimulating factor reverses neutropenia and reduces secondary infections in visceral leishmaniasis.
Badaró R; Nascimento C; Carvalho JS; Badaró F; Russo D; Ho JL; Reed SG; Johnson WD; Jones TC
J Infect Dis; 1994 Aug; 170(2):413-8. PubMed ID: 8035028
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in an infant who developed pancreatitis caused by meglumine antimoniate.
Kuyucu N; Kara C; Bakirtaç A; Teziç T
Pediatr Infect Dis J; 2001 Apr; 20(4):455-7. PubMed ID: 11332679
[TBL] [Abstract][Full Text] [Related]
4. Low dosage combination of meglumine antimoniate plus allopurinol as first choice treatment of infantile visceral leishmaniasis in Italy.
di Martino L; Mantovani MP; Gradoni L; Gramiccia M; Guandalini S
Trans R Soc Trop Med Hyg; 1990; 84(4):534-5. PubMed ID: 2091347
[No Abstract] [Full Text] [Related]
5. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group.
Laguna F; López-Vélez R; Pulido F; Salas A; Torre-Cisneros J; Torres E; Medrano FJ; Sanz J; Picó G; Gómez-Rodrigo J; Pasquau J; Alvar J
AIDS; 1999 Jun; 13(9):1063-9. PubMed ID: 10397536
[TBL] [Abstract][Full Text] [Related]
6. Electrocardiographic findings in Ethiopians on pentavalent antimony therapy for visceral leishmaniasis.
Berhe N; Abraham Y; Hailu A; Ali A; Mengistu G; Tsige K; Abebe Y
East Afr Med J; 2001 Nov; 78(11):608-10. PubMed ID: 12219968
[TBL] [Abstract][Full Text] [Related]
7. Acute pancreatitis associated with the administration of meglumine antimonate for the treatment of visceral leishmaniasis.
de Lalla F; Pellizzer G; Gradoni L; Vespignani M; Franzetti M; Stecca C
Clin Infect Dis; 1993 May; 16(5):730-1. PubMed ID: 8507769
[No Abstract] [Full Text] [Related]
8. Severe leucopenia during treatment of visceral leishmaniasis.
Hiçsönmez G; Jama H; Ozsoylu S
Trans R Soc Trop Med Hyg; 1988; 82(3):417. PubMed ID: 3232176
[No Abstract] [Full Text] [Related]
9. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients.
Delgado J; Macías J; Pineda JA; Corzo JE; González-Moreno MP; de la Rosa R; Sánchez-Quijano A; Leal M; Lissen E
Am J Trop Med Hyg; 1999 Nov; 61(5):766-9. PubMed ID: 10586909
[TBL] [Abstract][Full Text] [Related]
10. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru.
Miranda-Verástegui C; Llanos-Cuentas A; Arévalo I; Ward BJ; Matlashewski G
Clin Infect Dis; 2005 May; 40(10):1395-403. PubMed ID: 15844060
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of three chemotherapeutic schemes with meglumine antimoniate in the treatment of visceral leishmaniasis in the State of Pará, Brazil.
Marsden PD
Rev Inst Med Trop Sao Paulo; 1993; 35(6):589. PubMed ID: 7997767
[No Abstract] [Full Text] [Related]
12. Association of miltefosine with granulocyte and macrophage colony-stimulating factor (GM-CSF) in the treatment of cutaneous leishmaniasis in the Amazon region: A randomized and controlled trial.
Mendes L; Guerra JO; Costa B; Silva ASD; Guerra MDGB; Ortiz J; Doria SS; Silva GVD; de Jesus DV; Barral-Netto M; Penna G; Carvalho EM; Machado PRL
Int J Infect Dis; 2021 Feb; 103():358-363. PubMed ID: 33253864
[TBL] [Abstract][Full Text] [Related]
13. Pentavalent antimonial-induced torsade de pointes.
Ortega-Carnicer J; Alcázar R; De la Torre M; Benezet J
J Electrocardiol; 1997 Apr; 30(2):143-5. PubMed ID: 9141610
[TBL] [Abstract][Full Text] [Related]
14. Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial.
Firooz A; Khamesipour A; Ghoorchi MH; Nassiri-Kashani M; Eskandari SE; Khatami A; Hooshmand B; Gorouhi F; Rashighi-Firoozabadi M; Dowlati Y
Arch Dermatol; 2006 Dec; 142(12):1575-9. PubMed ID: 17178983
[TBL] [Abstract][Full Text] [Related]
15. Role of granulocyte-macrophage colony-stimulating factor as adjuvant treatment in neutropenic patients with bacterial and fungal infection.
Bodey GP; Anaissie E; Gutterman J; Vadhan-Raj S
Eur J Clin Microbiol Infect Dis; 1994; 13 Suppl 2():S18-22. PubMed ID: 7875147
[TBL] [Abstract][Full Text] [Related]
16. Combination of ganciclovir and granulocyte-macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients. The ACTG 073 Team.
Hardy D; Spector S; Polsky B; Crumpacker C; van der Horst C; Holland G; Freeman W; Heinemann MH; Sharuk G; Klystra J
Eur J Clin Microbiol Infect Dis; 1994; 13 Suppl 2():S34-40. PubMed ID: 7875151
[TBL] [Abstract][Full Text] [Related]
17. Retention of antimony in hair during leishmaniasis treatment.
Dorea JG; Merchan-Hamann E; Ryan DE; Holzbecher J
Clin Chim Acta; 1989 Feb; 179(3):341-5. PubMed ID: 2714007
[No Abstract] [Full Text] [Related]
18. Visceral leishmaniasis during pregnancy treated with meglumine antimoniate.
Utili R; Rambaldi A; Tripodi MF; Andreana A
Infection; 1995; 23(3):182-3. PubMed ID: 7499009
[TBL] [Abstract][Full Text] [Related]
19. Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients.
Ribera E; Ocaña I; de Otero J; Cortes E; Gasser I; Pahissa A
Am J Med; 1996 May; 100(5):496-501. PubMed ID: 8644760
[TBL] [Abstract][Full Text] [Related]
20. Randomized, double-blind study of stibogluconate plus human granulocyte macrophage colony-stimulating factor versus stibogluconate alone in the treatment of cutaneous Leishmaniasis.
Almeida R; D'Oliveira A; Machado P; Bacellar O; Ko AI; de Jesus AR; Mobashery N; Brito Santos J; Carvalho EM
J Infect Dis; 1999 Nov; 180(5):1735-7. PubMed ID: 10515844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
